DermTech: GSA recommends foundational assay included in DMT for VHA coverage

DermTech announced that U.S. General Services Administration has recommended the Company’s foundational assay included in the DermTech Melanoma Test or DMT for coverage by the Veterans Health Administration VHA . The VHA is the largest integrated health care system in the U.S. providing care at 1,298 health care facilities. This coverage recommendation makes the foundational assay of the DMT available to the VHA’s over 9 million enrolled Veterans. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value NPV . "We’re honored to join the VHA in bringing our non-invasive melanoma test to America’s Veterans," said Dan Visage, senior vice president of payor access, DermTech. "The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to teaming up with the VHA to make our test widely available to its beneficiaries in the coming months." DermTech’s total covered lives in the U.S. are now approximately 124M, which includes 68M for Medicare/Medicare Advantage and 56M for commercial and governmental payers.